Darunavir
Darunavir can induce a variety of delayed skin eruptions from mild MPE in most cases, to severe bullous cutaneous reactions in HIV infected patients (45, 61). A phase III randomized clinical trial performed in 604 patients treated with darunavir/r or LPV/r showed that the percentage of patients experiencing rash was higher in those receiving darunavir/r compared with others (16% vs 7%). Two patients receiving darunavir/r required treatment cessation due to a severe rash (45). Darunavir contains a sulfonamide moiety and should be used with caution in patients with a known sulfonamide allergy (62). Desensitization was reported to be successful in patients with non-immediate hypersensitivity reactions (NIHRs) to darunavir (63,64).